Cardiovascular Disease

Ethylenediaminetetraacetic acid-¹³C₄ (EDTA-¹³C₄) is the ¹³C-labeled Ethylenediaminetetraacetic acid (HY-Y0682). Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research.

SR-THAP is a γ-aminobutyric acid transporter 3 (GAT3) inhibitor with an IC₅₀ of 4.9 μM, and exhibits 42-fold and 23-fold selectivity over GAT1 and GlyT1, respectively. SR-THAP inhibits GABA uptake in mammalian cells. SR-THAP is applicable to the research of epilepsy, Alzheimer's disease and ischemic stroke.

BI-836880 is a humanized bispecific nanobody and a selective inhibitor of VEGF and ANG2, with a K_d of 16 pM for hANG2, an EC₅₀ of 1.4 nM for VEGF₁₆₅, and an EC₅₀ of 2.3 nM for VEGF₁₂₁. BI-836880 blocks ERK phosphorylation downstream of VEGF-A as well as TIE2 phosphorylation downstream of ANG2. BI-836880 does not inhibit ANG1-mediated TIE2 phosphorylation. BI-836880 exerts anti-angiogenic effects, reduces the number of immature endothelial vessels in tumor tissues, and inhibits tumor growth in preclinical models. BI-836880 can be used in the research of pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, colon cancer, and Lewis lung cancer.

L-Aspartyl-L-phenylalanine (Standard) is the analytical standard of L-Aspartyl-L-phenylalanine. This product is intended for research and analytical applications. L-Aspartyl-L-phenylalanine is a metabolite of aspartame that can inhibit angiotensin converting enzyme (ACE) purified from rabbit lungs with a Ki of 11 μM.

Mal-Val-Cit-PABC-Dexamethasone is a conjugate of the glucocorticoid receptor agonist Dexamethasone (HY-14648) and a ADC linker, which can be used for the synthesis of antibody-drug conjugates (ADC). Mal-Val-Cit-PABC-Dexamethasone is designed to deliver immunosuppressants to monocytes and/or monocyte-derived cells in a targeted manner.

BRL-52656 is a blood-brain barrier (BBB)-penetrable KOR receptor agonist that exhibits a biphasic effect. At low doses, BRL-52656 decreases blood pressure, whereas high doses have the opposite effect in spontaneously hypertensive rats. Additionally, BRL-52656 induces water diuresis by inhibiting the secretion of vasopressin (AVP).

DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling.

NI929 is a blood-brain barrier-permeable recombinant mouse aminopeptidase A (APA) inhibitor with a K_i value of 30 nM. NI929 is applicable to research on hypertension and Alzheimer's disease.

Docosahexaenoyl glycine is a PUFA analogue. Docosahexaenoyl glycine has activating effects on IKs channels and restore the function of IKs channels with LQT1 mutation.

Toralactone 9-O-triglucoside (Compound 2) is a phenolic trisaccharide. Toralactone 9-O-triglucoside can be isolated from Cassia seed. Toralactone 9-O-triglucoside can be used in the research of estrogen-related diseases such as breast cancer, prostate cancer, osteoporosis and cardiovascular disease.

(rac)-Mitiperstat ((rac)-AZD4831) is the racemic form of Mitiperstat (HY-145581). Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC₅₀s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC₅₀ of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease.

MRS542 is a nucleoside A3 AR antagonist with a pK_i of 8.74. MRS542 also acts as a partial agonist (pEC₅₀ = 7.76) in promoting β-arrestin translocation. MRS542 can be converted into an agonist by LUF6000 (HY-13236). MRS542 can be used for cardiovascular disease research.

β-Blocker B-24/76 is a beta adrenoceptor blocker. β-Blocker B-24/76 exhibits beta 1-adrenoceptor blocking and beta 2-adrenoceptor stimulating properties. β-Blocker B-24/76 can suppress the increased ornithine decarboxylase activity in hypertrophied hearts. β-Blocker B-24/76 can be used for the research of cardiovascular disease.

5-Nitro-1H-indazole-3-carbonitrile (DL0805) is a Rho kinase(ROCK) inhibitor with an IC₅₀ of 6.67 μM for ROCK-I. 5-Nitro-1H-indazole-3-carbonitrile reduces Norepinephrine (HY-13715)-induced transient contraction and inhibits contraction induced by increasing external calcium in the endothelium-denuded rings of rat models. 5-Nitro-1H-indazole-3-carbonitrile has a vasorelaxant activity but high toxicity. 5-Nitro-1H-indazole-3-carbonitrile can be used for cardiovascular diseases, especially hypertension research.

Ferroptosis-IN-11 (compound 43) is a ferroptosis inhibitor. Ferroptosis-IN-11 can inhibit Erastin (HY-15763) induced ferroptosis in HT-1080 human fibroblasts (EC₅₀=36 nM). Ferroptosis-IN-11 can be used in the study of cardiovascular disease and neurodegeneration.

Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects.

FAM labled Inclisiran sodiumis a FAM labled Inclisiran sodium.

Bovine Prothrombin is a glycoprotein with a molecular weight of 70 kDa and is composed of a single polypeptide chain. Prothrombin is activated by factors Va, Xa, and phospholipids to produce the serine protease thrombin.

Allotrap 07 is a synthetic peptide composed of residues 75-84 of HLA-B7, a class I MHC molecule. Allotrap 07 combined with Cyclosporin A (HY-B0579) induces donor-specific tolerance in rat cardiac allografts, significantly prolonging graft survival.

ALK5-IN-84 (Compound 23) is an ALK5 inhibitor with a pK_i value of 9.35 against hALK5. When administered via inhalation, ALK5-IN-84 exhibits significant ALK5 inhibitory activity. ALK5-IN-84 is promising for the development of inhaled ALK5 inhibitors.